Researchers at Johns Hopkins Medicine have developed a drug to treat Alzheimer’s disease, schizophrenia and sickle cell disease.

A world-first Edith Cowan University study has confirmed the link between Alzheimers and gut health, which could lead to new treatments.

A disease-modifying therapy for Alzheimer’s disease may involve the whole exchange of blood to decrease the formation of amyloid plaque.

Researchers believe these neurons could be transplanted into patients as a therapy for spinal cord injuries, Parkinsons and Alzheimers.

A new twin study suggests that the same genes may be behind the risk of both cardiometabolic diseases and dementia.

A large study from Lund University has shown that people with Alzheimer's disease can now be identified before they experience any symptoms.

Researchers have found that the disease’s debilitating symptoms may be the result of swelling caused by amyloid plaques in the brain.

Many laboratories, including our own, have detected different forms of LPS within neurons of the Alzheimer’s disease-affected human brain.

New study challenges existing ideas of how buildup of a protein called amyloid beta (Aβ) in the brain is related to Alzheimer’s disease.

Exercise can improve brain function and delay or prevent the onset of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease

By increasing the power and synchrony of the 40Hz brain rhythm, he lab has shown profoundly affects on several types of brain cells.

Researchers from UPitt developed a test to detect a novel marker of Alzheimer’s disease neurodegeneration in a blood sample.

OpenAI’s GPT-3 program can identify clues from spontaneous speech that are 80% accurate in predicting the early stages of dementia.

People who eat or drink more foods with antioxidant flavonols may have a slower rate of memory decline, according to a new study.

Johns Hopkins Medicine researchers say they discovered that a special sugar molecule could play a key role in the development of Alzheimer’s

A world-first study has confirmed the link between the two, which could lead to earlier detection and new potential treatments.

Compelling evidence suggests that the misfolding, aggregation, and cerebral deposition of amyloid-beta plays a central role in the disease.

A drug first developed to treat Alzheimer’s disease, schizophrenia and sickle cell disease reduces obesity and improves heart function.

Yale researchers have found that the disease’s debilitating symptoms may be the result of swelling caused by amyloid plaques in the brain.

A large study in Sweden has shown that people with Alzheimer's disease can now be identified before they experience any symptoms.